He established a new laboratory of tumor cell death at Blokhin Cancer Center with broad interests in cancer biology. The laboratory is studying the molecular mechanisms of cytocidal effects of small molecular weight compounds as perspective anticancer drug candidates. Our particular interest is novel DNA ligands, including the derivatives of anthraquinone and porphyrins that target the double helix and complex DNA structures. We also investigate the anti-apoptotic and pro-proliferation protein kinases of Pim family as a druggable target for newly developed indole based inhibitors.